Treace Medical Concepts, Inc. (TMCI)
NASDAQ: TMCI · Real-Time Price · USD
6.52
-0.07 (-1.06%)
At close: Nov 4, 2025, 4:00 PM EST
6.39
-0.13 (-1.99%)
After-hours: Nov 4, 2025, 5:34 PM EST
Treace Medical Concepts Stock Forecast
Stock Price Forecast
The 5 analysts that cover Treace Medical Concepts stock have a consensus rating of "Hold" and an average price target of $8.40, which forecasts a 28.83% increase in the stock price over the next year. The lowest target is $6.00 and the highest is $14.5.
Price Target: $8.40 (+28.83%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Treace Medical Concepts stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 5 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Hold Maintains $8 → $7 | Hold | Maintains | $8 → $7 | +7.36% | Oct 15, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $6.6 → $8 | Hold | Maintains | $6.6 → $8 | +22.70% | Sep 4, 2025 |
| UBS | UBS | Hold Maintains $8.6 → $6.5 | Hold | Maintains | $8.6 → $6.5 | -0.31% | Aug 8, 2025 |
| Stifel | Stifel | Hold Maintains $9 → $6 | Hold | Maintains | $9 → $6 | -7.98% | Aug 8, 2025 |
| UBS | UBS | Hold Maintains $10 → $8.6 | Hold | Maintains | $10 → $8.6 | +31.90% | May 9, 2025 |
Financial Forecast
Revenue This Year
231.62M
from 209.36M
Increased by 10.63%
Revenue Next Year
253.46M
from 231.62M
Increased by 9.43%
EPS This Year
-0.82
from -0.90
EPS Next Year
-0.73
from -0.82
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 238.9M | 262.7M | |
| Avg | 231.6M | 253.5M | |
| Low | 222.2M | 241.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 14.1% | 13.4% | |
| Avg | 10.6% | 9.4% | |
| Low | 6.1% | 4.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.83 | -0.70 | |
| Avg | -0.82 | -0.73 | |
| Low | -0.81 | -0.80 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.